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Abstract
Objective To assess the effects of selective cyclo-oxygenase-2
(COX 2) inhibitors and traditional non-steroidal
anti-inflammatory drugs (NSAIDs) on the risk of vascular
events.
Design Meta-analysis of published and unpublished tabular
data from randomised trials, with indirect estimation of the
effects of traditional NSAIDs.
Data sources Medline and Embase (January 1966 to April
2005); Food and Drug Administration records; and data on file
from Novartis, Pfizer, and Merck.
Review methods Eligible studies were randomised trials that
included a comparison of a selective COX 2 inhibitor versus
placebo or a selective COX 2 inhibitor versus a traditional
NSAID, of at least four weeks’ duration, with information on
serious vascular events (defined as myocardial infarction, stroke,
or vascular death). Individual investigators and manufacturers
provided information on the number of patients randomised,
numbers of vascular events, and the person time of follow-up
for each randomised group.
Results In placebo comparisons, allocation to a selective COX
2 inhibitor was associated with a 42% relative increase in the
incidence of serious vascular events (1.2%/year v 0.9%/year;
rate ratio 1.42, 95% confidence interval 1.13 to 1.78; P = 0.003),
with no significant heterogeneity among the different selective
COX 2 inhibitors. This was chiefly attributable to an increased
risk of myocardial infarction (0.6%/year v 0.3%/year; 1.86, 1.33
to 2.59; P = 0.0003), with little apparent difference in other
vascular outcomes. Among trials of at least one year’s duration
(mean 2.7 years), the rate ratio for vascular events was 1.45 (1.12
to 1.89; P = 0.005). Overall, the incidence of serious vascular
events was similar between a selective COX 2 inhibitor and any
traditional NSAID (1.0%/year v 0.9%/year; 1.16, 0.97 to 1.38;
P = 0.1). However, statistical heterogeneity (P = 0.001) was found
between trials of a selective COX 2 inhibitor versus naproxen
(1.57, 1.21 to 2.03) and of a selective COX 2 inhibitor versus
non-naproxen NSAIDs (0.88, 0.69 to 1.12). The summary rate
ratio for vascular events, compared with placebo, was 0.92 (0.67
to 1.26) for naproxen, 1.51 (0.96 to 2.37) for ibuprofen, and
1.63 (1.12 to 2.37) for diclofenac.
Conclusions Selective COX 2 inhibitors are associated with a
moderate increase in the risk of vascular events, as are high
dose regimens of ibuprofen and diclofenac, but high dose
naproxen is not associated with such an excess.
Introduction
Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are
widely used to treat pain, but their long term use is limited by
serious gastrointestinal side effects. Whereas NSAIDs inhibit the
two recognised forms of prostaglandin G/H synthase (also
referred to as cyclo-oxygenase), selective cyclo-oxygenase-2
(COX 2) inhibitors are selective inhibitors of the COX 2
isozyme.1 As the anti-inflammatory effects of NSAIDs were
believed to be mediated by inhibition of COX 2, and their
gastrointestinal side effects by inhibition of COX 1, people
hypothesised that selective COX 2 inhibitors would provide a
safer alternative to traditional NSAIDs. However, although some
studies have reported a lower incidence of upper gastrointestinal
complications with selective COX 2 inhibitors than with
traditional NSAIDs,2 3 recent concerns about the cardiovascular
safety of selective COX 2 inhibitors have limited their use.
Although the Vioxx gastrointestinal outcomes research
(VIGOR) trial reported a fivefold increase in myocardial infarc-
tion among participants allocated to rofecoxib (20 rofecoxib v 4
naproxen; P < 0.001),2 this difference might have occurred, at
least in part, because high dose naproxen inhibits platelet aggre-
gation throughout the dosing interval. However, the results of
the adenomatous polyp prevention on Vioxx (APPROVe) trial,
which was the first relatively large trial comparing a selective
COX 2 inhibitor with placebo, indicated that rofecoxib increased
the risk of vascular events by about twofold.4 Soon afterwards, the
adenoma prevention with celecoxib (APC) trial, comparing
celecoxib with placebo, reported a similar excess.5
The accumulating evidence suggests that selective COX 2
inhibitors are associated with an increased risk of vascular events,
but several important questions remain unanswered. Firstly, what
is the magnitude of any excess risk of myocardial infarction,
stroke, and vascular mortality? Secondly, is the excess risk of vas-
cular events dose related, and is the size of this risk different in
people who are also taking aspirin (which chiefly inhibits COX 1
at low doses6)? Thirdly, are traditional NSAIDs (which also inhibit
COX 2) associated with an increased risk of vascular events? We
did a meta-analysis of randomised trials that compared a
selective COX 2 inhibitor with placebo or a selective COX 2
inhibitor with a traditional NSAID in an attempt to answer these
questions.
A table, two extra figures, a statistical appendix, and extra references are on
bmj.com
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Methods
We used three steps to identify prospective randomised control-
led trials of a selective COX 2 inhibitor versus placebo, a selective
COX 2 inhibitor versus a traditional NSAID, or both. First we
approached the manufacturers of each of the selective COX 2
inhibitors—Merck (rofecoxib, etoricoxib), Novartis (lumiracoxib),
and Pfizer (celecoxib, valdecoxib). Then we searched the Food
and Drug Administration website for data presented at the
Cardiorenal Advisory Committee meeting in February 2005.
Finally, we used the modified Cochrane strategy7 combined with
the generic names of each of the individual selective COX 2
inhibitors as keywords to search Medline and Embase from
January 1966 to April 2005.
Randomised trials involving at least four weeks’ scheduled
treatment were eligible if they included at least one comparison
of a selective COX 2 inhibitor versus placebo or a selective COX
2 inhibitor versus a traditional NSAID and had recorded serious
(that is, admitted to hospital or fatal) cardiovascular events. The
pre-specified outcomes were “serious vascular event,” as defined
by the Antiplatelet Trialists’ Collaboration (that is, non-fatal
myocardial infarction, non-fatal stroke, or vascular death)8; fatal
or non-fatal myocardial infarction; fatal or non-fatal stroke; and
vascular death (including death from myocardial infarction or
stroke). The manufacturers and individual investigators provided
summary design details for each trial and information on the
process (if any) by which vascular events were adjudicated. All of
the manufacturers provided written confirmation that the data
provided were complete: Pfizer had locked their data at 31 Octo-
ber 2004, whereas Merck and Novartis had locked their
databases at the end of January 2005. We requested numbers of
events and person time at risk for each trial, where available, but
in a few cases we estimated data from published results or the
Food and Drug Administration website.9
On the basis of the known pharmacokinetic and pharmaco-
dynamic properties of the NSAIDs studied (which raised the
hypothesis that naproxen might have aspirin-like antiplatelet
effects), we prospectively specified that analyses of a selective
COX 2 inhibitor versus NSAID were to be subdivided into those
involving naproxen and those concerning other (non-naproxen)
NSAIDs.
We derived rate ratios and their confidence intervals for each
of the pre-specified comparisons by using the Peto “one step”
approximation (see statistical appendix on bmj.com).10 In figures
and in the text, we have used 99% confidence intervals for indi-
vidual comparisons to allow for the multiplicity of analyses,
reserving 95% confidence intervals for subtotals.
Results
Study population
Tabular data were available from 138 randomised trials involving
a comparison of a selective COX 2 inhibitor versus placebo or
versus a traditional NSAID (or both), in which there were a total
of 145 373 participants (see table on bmj.com).w1-w90
Comparisons of selective COX 2 inhibitor versus placebo
Figure 1 shows meta-analyses of a selective COX 2 inhibitor
versus placebo, subdivided by individual selective COX 2 inhibi-
tor, for each of the primary outcomes. Overall, among 121
placebo controlled trials, 216 vascular events occurred during
18 490 person years of exposure to a selective COX 2 inhibitor
(1.2%/year) compared with 112 during 12 639 person years of
placebo (0.9%/year), corresponding to a 42% proportional
increase in the incidence of a first serious vascular event (rate
ratio 1.42, 95% confidence interval 1.13 to 1.78; P = 0.003). We
found no evidence that the proportional excess incidence of vas-
cular events varied among the different selective COX 2
inhibitors (heterogeneity 2 = 0.5, df = 4; P = 1.0). However, as
only two selective COX 2 inhibitors (rofecoxib and celecoxib)
had recorded appreciable numbers of such outcomes, the power
to identify any real differences that might exist between selective
COX 2 inhibitors was limited. In the group of trials analysed, this
proportional difference corresponded to an excess of 3 (95%
confidence interval 1 to 5) people with a vascular event per 1000
allocated to a selective COX 2 inhibitor per year.
We found an almost twofold proportional increase in
myocardial infarction (rate ratio 1.86, 1.33 to 2.59; P = 0.0003)
(fig 1), corresponding to an excess of 3 (1 to 4) people with myo-
cardial infarction per 1000 allocated to a selective COX 2 inhibi-
tor per year. We found no significant heterogeneity in the rate
ratios for myocardial infarction among individual selective COX
2 inhibitors (heterogeneity 2 = 1.0, df = 4; P = 0.9). We found no
difference in the incidence of stroke (rate ratio 1.02, 0.71 to 1.47;
P = 0.9), corresponding to an absolute difference of 0 ( − 2 to
1)/1000/year, and the summary rate ratio for vascular death
(1.49, 0.97 to 2.29; P = 0.07), although it did not reach statistical
significance, corresponded to an absolute excess of 1 (0 to
2)/1000/year.
Duration
Of the 121 placebo controlled trials, nine were long term trials
with one year or longer of scheduled treatment (mean 139
weeks) and 112 were shorter trials (mean 11 weeks). Around two
thirds of the vascular events had occurred in the nine long term
trials. In these long term trials, allocation to a selective COX 2
inhibitor was associated with a 45% increase in the incidence of
vascular events (rate ratio 1.45, 1.12 to 1.89; P = 0.005) (fig 2),
with no significant heterogeneity between the event rate ratios in
the trials (heterogeneity 2 = 13.4, df = 8; P = 0.1).
Dose
Too few vascular events were available to allow us to assess dose-
response in placebo controlled trials of etoricoxib, lumiracoxib,
or valdecoxib. For rofecoxib, 85% of vascular events among
patients allocated to a selective COX 2 inhibitor occurred at a
dose of 25 mg daily, with few events at lower or higher daily
doses, so we could not evaluate dose dependence. For celecoxib,
we found a significant trend towards an increased incidence of
serious vascular events with higher daily doses (trend P = 0.03)
(fig A on bmj.com).
Aspirin
Among the 84 placebo controlled trials that allowed concomi-
tant use of aspirin for which data were available, we found no
significant heterogeneity of the summary rate ratios for vascular
events among aspirin users and non-users (heterogeneity
2 = 0.0, df = 1; P = 0.9) (fig B on bmj.com). We found a similar
lack of heterogeneity for myocardial infarction, stroke, and
vascular death (data not shown).
Comparisons of selective COX 2 inhibitor versus traditional
NSAID
Overall, we found no significant difference in the incidence of a
serious vascular event between participants allocated to a
selective COX 2 inhibitor and those allocated to a traditional
NSAID—340 vascular events during 33 260 person years of
exposure to a selective COX 2 inhibitor (1.0%/year) versus 211
vascular events during 23 325 person years with a traditional
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NSAID (0.9%/year) (rate ratio 1.16, 0.97 to 1.38; P = 0.1) (fig 3).
However, we found marked heterogeneity between the rate
ratios for vascular events in trials comparing a selective COX 2
inhibitor with naproxen and those comparing a selective COX 2
inhibitor with a non-naproxen NSAID (2 = 10.2, df = 1;
P = 0.001). We found similar heterogeneity for myocardial
infarction (2 = 4.3, df = 1; P = 0.04), stroke (2 = 3.6, df = 1;
P = 0.06), and vascular death (2 = 5.3, df = 1 P = 0.02).
Any selective COX 2 inhibitor versus naproxen
Overall, compared with naproxen, allocation to a selective COX
2 inhibitor was associated with a highly significant increase in the
incidence of a vascular event (rate ratio 1.57, 1.21 to 2.03;
P = 0.0006) and a twofold increased risk of a myocardial
infarction (2.04, 1.41 to 2.96; P = 0.0002) (fig 3).We found no sig-
nificant difference in the incidence of stroke (rate ratio 1.10, 0.73
to 1.65; P = 0.7) or of vascular death (1.47, 0.90 to 2.40; P = 0.1).
Any selective COX 2 inhibitor versus a non-naproxen NSAID
Overall, we found no significant difference in the incidence of a
vascular event (rate ratio 0.88, 0.69 to 1.12; P = 0.3), myocardial
infarction (1.20, 0.85 to 1.68; P = 0.3), or vascular death (0.67,
0.43 to 1.06; P = 0.09), but a selective COX 2 inhibitor was asso-
ciated with a significantly lower incidence of stroke than any
non-naproxen traditional NSAID (rate ratio 0.62, 0.41 to 0.95;
P = 0.03) (fig 3). Comparisons of a selective COX 2 inhibitor with
ibuprofen (rate ratio 0.85, 99% confidence interval 0.49 to 1.46;
P = 0.4), a selective COX 2 inhibitor versus diclofenac (0.85, 0.56
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Fig 1 Comparison of effects of different selective COX 2 inhibitors versus placebo on vascular events, myocardial infarction, stroke, and vascular death. Event
numbers and person years of exposure, with corresponding mean annual event rates in parenthesis, are presented for patients allocated to selective COX 2 inhibitor
and placebo. Event rate ratios for subtotals, with 95% confidence intervals, are indicated by a diamond; rate ratios for individual selective COX 2 inhibitors, with 99%
confidence intervals, are indicated by a square and horizontal line. Diamonds to the right of the solid line indicate hazard with a selective COX 2 inhibitor compared with
placebo, but this is conventionally significant only if the diamond does not overlap the solid line
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to 1.27; P = 0.3), and a selective COX 2 inhibitor versus any other
non-naproxen NSAID (2.21, 0.49 to 10.03; P = 0.2) yielded simi-
lar rate ratios for vascular events (test for heterogeneity 2 = 2.6,
df = 2; P = 0.3) (fig 3).
Comparisons of traditional NSAID versus placebo
We combined direct estimates of treatment effect (from trials
involving a comparison of an NSAID versus placebo) with
indirect information (from a comparison of trials of a selective
COX 2 inhibitor versus placebo and a selective COX 2 inhibitor
versus NSAID) (see statistical appendix on bmj.com). The
summary rate ratio for vascular events, in comparison with
placebo, was 0.92 (95% confidence interval 0.67 to 1.26) for
naproxen, 1.51 (0.96 to 2.37) for ibuprofen, and 1.63 (1.12 to
2.37) for diclofenac.
Discussion
When we considered all the randomised trial data, selective COX
2 inhibitors were associated with a highly significant 1.4-fold
increased risk of serious vascular events, largely due to a twofold
increased risk of myocardial infarction. Although we found no
significant excesses in the incidence of stroke or vascular death,
the confidence intervals for each were wide, so we could not
exclude a clinically important excess. If, as some people have
suggested (on the basis of the delayed divergence of survival
curves), the hazard emerges only after a year or 18 months,4 5
then combining short term and long term trials might under-
estimate the effects of long term exposure to a selective COX 2
inhibitor. We were not able to assess time dependent variation in
the rate ratio because we sought numbers of events and person
time only for the whole period of follow-up in each trial.
However, as figure 2 clearly shows, when all the long term trials
are considered, the summary rate ratio is similar to that from
short term and long term trials combined and somewhat smaller
than the twofold to threefold excess suggested by the combined
results of the APC and APPROVe studies.4 5
Not all of the trials had independent adjudication of vascular
events, so a bias towards the null is possible owing to
non-differential misclassification of vascular outcomes in those
trials without independent adjudication. As more than 70% of
the vascular events occurred in trials that were adjudicated, the
potential for misclassification is limited. Indeed, the summary
rate ratio for a selective COX 2 inhibitor versus placebo among
adjudicated trials was 1.45 (95% confidence interval 1.12 to
1.89), which is very similar to the estimate among all trials of 1.42
(1.13 to 1.78). A further potential source of bias was our
prospective decision to limit eligibility to trials of at least four
weeks’ duration, because this resulted in the exclusion of two
small short term randomised trials of parecoxib (the intrave-
nously administered pro-drug of valdecoxib) and valdecoxib ver-
sus placebo among patients having coronary artery bypass
grafting,11 12 in which the risk of vascular events was increased
threefold.13 If these two trials had been included, the summary
rate ratio for a selective COX 2 inhibitor versus placebo would
have been 1.49 (1.20 to 1.85). Hence, although we cannot
exclude the possibility that, at least in the context of vascular sur-
gery, the proportional increase in risk of a vascular event is
higher with parecoxib or valdecoxib than with other selective
COX 2 inhibitors, the exclusion of these trials had a small effect
on the overall summary rate ratio for a selective COX 2 inhibitor
versus placebo.
The available data from placebo controlled trials were
inadequate to allow assessment of whether the cardiovascular
risks of selective COX 2 inhibitors are dose dependent (fig A on
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Fig 2 Comparison of effects of selective COX 2 inhibitors versus placebo among trials with scheduled duration of at least one year. Symbols and conventions are as
in fig 1
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bmj.com). Although we found a weak trend towards larger risks
with higher daily doses of celecoxib, this result was driven by the
results of one trial.5 We were also unable to determine reliably
whether the cardiovascular effects of selective COX 2 inhibitors
might differ among aspirin users and non-users (fig B on
bmj.com).
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Fig 3 Comparison of effects of selective COX 2 inhibitors versus traditional NSAIDs on vascular events, myocardial infarction, stroke, and vascular death. Symbols
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Cardiovascular effects of traditional NSAIDs
As traditional NSAIDs inhibit the COX 2 enzyme, these drugs
might also be associated with an increased risk of vascular
events.14 As NSAIDs were originally developed for the relief of
pain, long term placebo controlled trials have not been done. A
few traditional NSAIDs with prominent effects on the COX 1
isozyme, such as indobufen and flurbiprofen, have been tested as
potential antiplatelet agents in small studies,15 16 but no
adequately powered long term randomised trials have assessed
drugs without such antiplatelet effects. As the plasma half life of
naproxen is around 14 hours, a regimen of 500 mg twice daily
results in sustained inhibition of COX 1 dependent thrombox-
ane biosynthesis, whereas both ibuprofen and diclofenac have
much shorter half lives (one to two hours), and standard twice or
three times daily regimens have only transient effects. We there-
fore hypothesised that the cardiovascular effects of naproxen
would differ from those of non-naproxen NSAIDs. Our results
indicated that high dose ibuprofen (800 mg three times daily)
and high dose diclofenac (75 mg twice daily) were each
associated with an increased risk of vascular events, but that the
risks of high dose naproxen (500 mg twice daily) were
substantially smaller. We had insufficient information to
determine whether naproxen was protective. Uncertainty
remains, however, as to whether the cardiovascular effects of
standard (that is, lower) daily doses of these drugs would differ
from those identified in this meta-analysis, and this is an impor-
tant topic for future research.
Estimating absolute risk
In this particular group of trials, allocation to a selective COX 2
inhibitor was associated with around three extra people having a
vascular event per 1000 per year, with most of this excess attri-
butable to myocardial infarction. The annual excess incidence
associated with full compliance with a selective COX 2 inhibitor
would be expected to be larger than this, however. In the
APPROVe study, for example, approximately one third of
randomised patients discontinued study treatment before the
end of the study.4 If this discontinuation rate was typical, the
absolute excess incidence of vascular events produced by full
compliance with a selective COX 2 inhibitor might be four or
five additional patients having a vascular event per 1000 treated
per year overall, with a smaller excess among those at lower than
average risk (such as young women with rheumatoid arthritis)
and a higher excess in those at above average risk (such as older
patients with established atherosclerotic disease).
Study limitations
The chief limitation of this study is the relatively small number of
events available for analysis, which limits assessment of the haz-
ards of the various different selective COX 2 inhibitors and tra-
ditional NSAIDs in particular clinical circumstances. We were
also limited to analysing tabular summaries of data, which
prevented us from assessing the timing of the hazard or variation
in the rate ratio among particular subgroups of patients. More-
over, we limited attention to cardiovascular hazards, whereas the
choice between different anti-inflammatory regimens also needs
to take account of differences in their gastrointestinal effects.
Some of these outstanding uncertainties may be resolved by a
planned meta-analysis of data on individual patients from these
trials.
Conclusions
This meta-analysis has shown that selective COX 2 inhibitors are
associated with a moderate increase in the risk of vascular events,
as are high dose regimens of ibuprofen and diclofenac, but that
high dose naproxen is not associated with such an excess. As dif-
ferences between anti-inflammatory regimens are likely to be
small, very large randomised trials will be needed if we are to
identify which anti-inflammatory drug regimens minimise the
overall burden of adverse gastrointestinal and cardiovascular
outcomes.
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